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Abstract 
Corticosteroids are the most potent and reliable of the available agents among the anti-
inflammatory drugs, and have assumed a major role in the management of asthma. This has 
subsequently resulted in the global widespread use of inhaled corticosteroids (ICS). A variety 
of studies have been undertaken to examine the effects of ICS on voice production among 
people with asthma. Most research suggests that the long-term use of ICS has a negative 
effect on voice production. However, the results of these studies are limited because of the 
reliance upon examining an asthmatic population and not consistently recording the dose 
prescribed. As a result, one cannot exclude that some of the voice problems may have been 
previously caused by asthma and thus, the contributing effects of ICS are obscured. 
Therefore, an ideal approach to examine the influence of ICS on voice is to test its short-term 
effects on healthy individuals, using a specific ICS (Fluticasone Propionate) at a fixed dose 
(1000 µg/Day). Thirty healthy adults (15 females & 15 males) aged between 18 to 30 years 
participated in this study. All participants were non-smokers with no history of speech, 
language or voice disorder. No participants had a history of asthma, respiratory illness 
hospital admission or inhaler use within the past 3 months. All participants followed the 
treatment regime often prescribed by physicians (in Canterbury region) for treating asthma 
(500 µg in morning & 500 µg in evening). Each participant self administered (inhaled) two 
puffs of ICS in the morning and again in the evening over a six day period. Voice samples 
were audio-recorded prior to undergoing the ICS regime, at various points during the ICS 
regime, and at the conclusion of ICS regime. Each participant’s audio-recorded samples were 
submitted for acoustic analysis using a commercially available speech analysis system (CSL 
4300B, Kay Elemetrics, 1994). Three measures were performed, (1) vocal fundamental 
frequency (F0), (2) long-time spectral analysis (LTAS) and (3) formant frequency and 
formant frequency bandwidth. 
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The result of this study indicates that ICS does have an effect on acoustic properties of voice. 
These effects were more evident in connected speech compared to isolated vowel 
productions. In particular, the spectral tilt and first spectral peak of continuous speech 
samples were found to change from baseline. The current results are discussed in regard to 
the phonatory deterioration associated with ICS use. The present study provides a framework 
for developing ICS treatment for respiratory disease in the phase of minimizing adverse 
effects on voice. 
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Introduction 
         Steroids can be divided into two categories, (1) anabolic steroids and (2) 
corticosteroids. Anabolic steroids are a class of steroid hormones related to the hormone 
testosterone. The steroid serves to increase protein synthesis within cells, which results in the 
build-up of cellular tissue in muscle called anabolism (de Bolster, 1997). Anabolic steroids 
also have androgenic properties, such as the development of masculine characteristics (e.g., 
body hair). The word anabolic derived from the Greek word anabolein, "to build up", and the 
word androgenic from the Greek andros, "man" + genein, "to produce". A corticosteroid is a 
steroid hormone that is produced naturally in the adrenal cortex. Corticosteroids are used by 
physicians to treat inflammatory conditions, such as asthma, allergic rhinitis, atopic 
dermatitis, rheumatoid arthritis, chronic low back pain, shoulder injuries, polymyalgia, and 
preventing rejections in transplants (Barnes, 2001; Gaffo, Saag, & Curtis, 2006). 
History of corticosteroids 
            Cortisol and adrenocorticotropic hormones (ACTH) were isolated and synthesised 
independently by Reichestein (1935). Philip Hench, a rheumatologist working at Mayo Clinic 
was the first to demonstrate the clinical efficacy of cortisone in 1948. He did this by giving 
intravenous injections of ACTH to patients with rheumatic arthritis (Glyn, 1998). Boardley, 
Carey and Harvey (1949) at John Hopkins University were the first to use cortisone in 
patients with asthma. They described five patients with asthma, all of whom had eosinophilic 
sputum, who improved rapidly with intramuscular injections of ACTH over a three week 
period. They later replicated the study and confirmed these observations in a larger group of 
patients. Subsequently, oral cortisone was shown to be an effective replacement for injections 
in patients with difficulty to control asthma. Oral steroids are now frequently used for 
patients with severe asthma but it is clear that side effects are a major problem, resulting in 
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stunting of growth in children, osteoporosis and metabolic disturbances (Medical Research 
Council, U.K, 1956).  
         To reduce systemic side effects, the need to give corticosteroids by inhalation was 
suggested by the Medical Research Council (U.K) in 1956. This has led to the development 
of two synthetic steroids, beclomethasone dipropionate (BDP) and betamethasone-17-
valerate to be used for inhalation. Brown, Storey and George (1972) established that inhaled 
BDP was effective in reducing the need for oral corticosteroids and in many patients achieved 
better control of asthma. Fluticasone Propionate (FP) has become the most commonly 
prescribed inhaled corticosteroid (ICS) for patients with asthma and reactive airway disease 
because of its potency and safety margin (DelGaudio, 2002), and the activity of FP being two 
times greater than BDP (Ayres, Bateman, Lundback & Harris, 1995; Clark & Lipworth, 
1997; Fabbri, Burge & Croonenborgh, 1993). FP is a highly lipophilic molecule (topical 
potency) with good uptake, binding and retention characteristics in human lung tissue. FP has 
rapid binding property with the receptors present on the cell membrane and acting rapidly on 
inflammatory cells (Fuller, Johnson & Bye, 1995). Orally administered FP is rapidly 
metabolized on the first pass through the liver, resulting in less than 1% oral bioavailability 
and has a longer elimination half-life than BDP (Harding, 1990). 
Steroids and Asthma 
Corticosteroids are the most potent and reliable of the available agents among the 
anti-inflammatory drugs, and have assumed a major role in the management of asthma 
(Szelfler, 1991). This has subsequently resulted in the widespread use of ICS. The 
vasoconstrictor activity of ICS aids to reduce bronchial mucosal oedema and thickening. ICS 
can be used as a monotherapy (i.e., using a single drug for treatment) or as a combination 
production (i.e., use of two or more drugs). The co-administration of an ICS with a long-
lasting beta-2 (β2) agonist in a single inhaler has greatly simplified asthma therapy. The 
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action on β2 agonists contributes to relaxation of smooth muscles, resulting in dilation of the 
bronchial passages (Kips & Pauwels, 2001). 
       The two combination inhalers currently available are Symbicort and Seretide (Lotvall, 
2004). Symbicort combines budesonide (a form of BDP) and formoteral in a single inhaler. 
Seretide combines salmeterol and FP (double dose of BDP) in a single inhaler. These inhalers 
comply with Step 3 (total 5 steps) of the international guidelines established by Global 
Initiative for Asthma (GINA) for asthma control (Humbert, Anderson & Buhl, 2008). The 
guidelines recommend the addition of a long-acting β2-agonist to ICS in patients who are 
inadequately controlled on ICS alone  
There are currently two approaches for treating asthma using combination therapy (1) 
fixed and (2) adjustable dosing. Fixed dosing with either Symbicort or Seretide provides 
effective asthma control in line with guideline goals recommended by GINA (Humbert, et al., 
2008). However, given the inherent variability of asthma, there is increasing evidence that 
adjusting the dose of ICS according to fluctuations in symptoms is beneficial (Lotvall, 2004). 
Findings from a series of studies comparing fixed and adjustable symptom-guided dosing 
regimens demonstrate that adjustable dosing may improve asthma control at an overall lower 
steroid dose (Lotvall, 2004). However, in cases of persistent acute asthmatic symptoms the 
patients are using very high doses of ICS for longer periods (Hanania, Chapman, & Kesten, 
1995). The long-term use of ICS may also reduce the number of mast cells in airway mucosa 
and decrease the immediate response to allergen and exercise (Barnes, 1993). 
 As with many types of medication that are taken for an extended period, 
corticosteroids should always be withdrawn slowly and with medical advice. While taking 
the medication, the adrenal gland’s natural production of the steroid diminishes significantly. 
A process of gradual withdrawal from the medication is required to allow the adrenal gland 
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an opportunity to restart the natural synthesis of steroids again (Nahaczewski, Fowler, & 
Hariharan, 2004). 
Complications of ICS 
       Systemic complications occur when using ICS because up to 80% of the dose delivered 
by a conventional metered-dose inhaler (MDI) is swallowed. Systemic side effects are dose-
dependent, and obvious differences exist between ICSs in their ability to cause systemic 
glucocorticoid activity (Jones, Toogood, & Crilly, 1988). Some researchers have speculated 
that a “residue” from the inhaled substance irritates the pharyngolaryngeal mucosa. Both the 
propellant and lubricant components of MDI preparations have a pro-inflammatory local 
effect (Roland, Bhalla, & Earis, 2004). Long-term adverse effects associated with chronic 
corticosteroid use include osteoporosis, cushingnoid appearance, accelerated atherosclerosis, 
early cataracts, skin thinning and pupura (Cope & Bova, 2008). Some of the probable causes 
of the complications include:  
• The steroid (e.g., preparation, carrier substance, dose of steroid, and regime). 
• The manner in which it is propelled into the airways (i.e. the inhaler device). 
• Intrinsic inflammation of the upper airway in asthmatic patients. 
• Mechanical irritation because of cough. 
• Inflammatory disease (e.g., rhinitis and postnasal catarrh) and inflammatory stimuli 
(e.g., smoking and noxious agents in the workplace). 
Inhaled Corticosteroid (ICS) and Voice Production 
The impact of ICS on voice production has received considerable research attention 
(Gallivan, Gallivan & Gallivan, 2007). A majority of this research has focused on individuals 
with asthma. The bulk of these studies suggest that ICS has a negative impact on voice 
production (Bhalla, Watson, Taylor, Jones & Roland, 2009). However, there are studies 
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showing no adverse affects of ICS on voice production (Shaw & Edmunds, 1986) as well as 
an improvement in voice following ICS (Meyer, Scott & Chapman, 2001).  A chronological 
review of the salient literature follows.   
Williams et al. (1983) studied 14 patients for 18 months who presented with a 
complaint of severe and persistent dysphonia, while receiving ICS for chronic asthma. The 
average dose given was 400 µg/day of BDP. They observed that in 9 (64%) patients a 
characteristic bilateral adductor vocal fold abnormality (i.e., a bowing of the vocal cords 
during phonation) was present during laryngoscopic evaluation. They concluded that the 
etiology of dysphonia is a steroid myopathy affecting the thyroatrytenoid (i.e., vocal fold) 
muscles. With cessation of ICS, the dysphonia and vocal cord deformity resolved completely 
within 12 weeks. 
Shaw and Edmunds (1986) examined 129 children between the ages of 6 to 15 years 
during a 6-month period of regular ICS use. They divided the children into two groups 
depending on the dose of ICS used per day. A total of 91 children were receiving less than 
500 µg per day (range from 100-400 µg per day) and 38 were receiving more than 500 µg per 
day (range from 500-1500 µg per day) from the beginning of the study. At the conclusion of 
the 6-month period, the children were asked if they had a sore throat or hoarse voice. A total 
of 13 children reported having a sore throat. They found that dysphonia was not a problem in 
any of the two groups, although no objective (e.g., acoustic) measures of dysphonia were 
performed. 
Shim and Williams (1987) studied 12 individuals with asthma who complained of 
severe cough and wheezing after using ICS (containing BDP). Each participant was required 
to take three puffs of BDP (120 µg), as well as three puffs of a placebo (in random order) 
using a metered dose inhaler (MDI). Following each puff, the total number of coughs elicited 
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by using the inhaler was tabulated. Across the three puffs, the group was found to produce a 
mean of 31 coughs following BDP and 19 coughs following the placebo. The results suggest 
that use of an inhaler device can lead to coughing, wheezing, and use of BDP is particularly 
prone to eliciting these negative side effects. 
Williamson, Matusiewicz, Brown, Greening and Crompton (1995) assessed the 
prevalence of throat and voice symptoms in asthmatic patients compared to a non-asthmatic 
(control) group. A total of 255 out-patients using ICS (the average dose used was 800 µg- 
1000 µg) and 100 controls were surveyed. A total of 147 (58%) patients reported dysphonia 
or throat symptoms compared to 13% of the control group. Significantly more women (80%) 
reported having throat or voice symptoms in comparison to men (64%). Throat symptoms 
were more prevalent in patients using higher doses of ICS. However, the authors could not 
exclude that some of the voice problems may have been caused by asthma and may have 
actually improved on ICS therapy. 
Hone et al. (1996) investigated 20 asthmatics, using a perceptual rating score of 
hoarseness, videolaryngoscopy (VLS) and videostroboscopy, prior to and after three months 
of high dose ICS therapy (1000 µg/day). A group of 22 healthy volunteers acted as controls. 
Erythema and oedema was noted in 10 (45%) asthmatics and vocal fold nodules in two (9%) 
asthmatics. Four (18%) of the control group had erythema and oedema. After 3 months of 
ICS therapy, improvement in voice was noted in 2 (33%) of the 6 patients complaining of 
hoarseness. This was associated with resolution of a vocal fold nodule in one participant and 
resolution of erythema in another. One asthmatic developed a mild glottic chink, which was 
attributed to steroid induced myopathy of the vocal folds. The researchers concluded that 
asthmatics have significantly more vocal fold pathology than healthy controls.  
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Lavy, Wood, Rubin and Harries (2000) performed a study on 22 patients receiving 
ICS for asthma, who had developed persistent troublesome hoarseness subsequent to the 
commencement of aerosol steroid treatment. Each patient was formally assessed in a voice 
clinic with VSL and stroboscopy. After this, a sample of speech and other vocal parameters 
were recorded using the “aerophone” and analysed using a visi-speech vocal analysis 
program. Using laryngoscopy, the vocal fold position, supraglottic hyperfunction, and 
mucosal changes were evaluated. For objective acoustic measures, mean fundamental 
frequency (F0), maximum phonation time and jitter (i.e., cycle-to-cycle variation in F0) were 
performed. The researchers found that 17 (77%) patients complained of hoarseness on a daily 
bases. Eight (36%) patients complained of other side effects, in most cases this was dryness 
and soreness of the throat. In nine (41%) patients there was some evidence of poor vocal fold 
positioning detected by laryngologists. Marked supraglottic hyperfunction and arytenoid 
over-ride was found in five (23%) patients. In 58% of the patients, opposition abnormalities 
were noted, supraglottic hyper function was noted in 40% patients. The acoustic analyses 
were revealing of cycle-to-cycle irregularity in 39% patients. Maximum phonation time was 
also reduced in 73% of the patients. A primary cause of these findings was attributed to use 
of ICS. 
Meyer et al. (2001) recruited 77 patients who took 1000 µg/day of inhaled ICS (BDP) 
and 10 patients who received occasional ICS treatment. At 2, 4, 8, 12 and 16 weeks, each 
patient’s voice was audio recorded for later acoustic analysis. The results of the acoustic 
analysis indicated that mean jitter values did not differ significantly between the two groups. 
However, mean shimmer (i.e., cycle-to-cycle variation in vocal loudness) scores fell 
significantly (p<0.05) in the active treatment group. The researchers concluded that 
individuals with asthma who take 1000 µg/day of inhaled BDP could actually show an 
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improvement in their voice, suggesting that the dosage regime used in ICS is an important 
factor in regard to vocal function. 
DelGaudio (2002) described a condition that is referred to as steroid inhaler laryngitis, 
a clinical entity that is caused by FP inhalation and manifested by dysphonia, throat clearing 
and fullness. The study population consisted of 20 patients with reactive airway disease and 
dysphonia, who were receiving inhaled FP therapy. The dose of FP used by the patients 
varied from 220 µg to 880 µg per day. The researcher reported laryngeal findings ranging 
from mucosal oedema, bilateral severe vocal cord and arytenoid hyperemia, thickening, 
leukoplakia, granulation, and candidiasis. In two cases, the vocal fold changes were severe 
enough to prompt direct laryngoscopy and biopsy to rule out malignancy. The researcher 
concluded that steroid inhaler laryngitis is a form of chemical laryngopharyngitis induced by 
topical steroid administration. Moreover, the severity of vocal fold mucosal changes was 
attributed to greater potency of FP as compared to other ICS.  
Mirza, Schwartz and Ozerkis (2004) conducted a retrospective study to describe voice 
and laryngeal changes in patients who were administered a combination therapy of a 
corticosteroid (FP) and a long-term acting β2 agonist (LABA) (salmeterol xinafoliate) for 
treatment of asthma. All patients complained of dysphonia after starting the combination 
therapy over the last 1 to 6 months. Videostroboscopic and stroboscopy examinations were 
performed later to evaluate the laryngeal and voice changes. Videostroboscopy revealed 
vascular lesions like dilated blood vessels, and small areas of haemorrhages. Stroboscopy 
revealed that hemorrhagic areas displayed reduced amplitude of vibration and decreased 
propagation of the mucosal wave. Adding to this area of thickening, irregularity and 
leukoplakia involving the vibratory margins of the vocal folds was found. These findings 
were suggestive of vocal fold trauma and irritation. In summary this study highlighted the 
negative effects of ICS on the larynx and voice production. 
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Krecicki et al. (2006) assessed the influence of ICS on vocal fold functioning in 
patients treated for bronchial asthma. Participants consisted of 50 patients who received ICS 
(BDP & FP) for treatment of asthma and a control group of 41 healthy volunteers. All 
patients were non-smokers and had been receiving ICS for at least 18 months. The patients 
and the control group underwent a detailed laryngoscopic examination to evaluate the effects 
of ICS on larynx. The results showed vocal fold atrophy in 10 (20%) patients, atrophy of 
laryngeal mucosa in 22 (44%) patients and vocal fold bowing in 10 (20%) patients. All the 
above changes pertaining to the vocal folds were found in the patients, but no such changes 
were observed in the control group. The researchers concluded that the vocal fold pathologies 
were caused by inhaling corticosteroids. Moreover, vocal fold atrophy was significantly 
higher among those patients with the longest history of asthma treatment (minimum of 5 
years of therapy). There was no correlation between laryngeal changes and doses of ICS.  
Kosztyla-Honja, Rogowski, Rutkowski, Pepinski and Rycko (2006) examined the 
influence of ICS on the phonatory function of the larynx in patients suffering from asthma. 
The effect of ICS was measured in 15 patients after 30 minutes of ICS administration. 
Evaluation of voice function was done subjectively and objectively by using 
videostroboscopy. The researchers found that administration of ICS resulted in incidents of 
cough, mouth and throat dryness, sensation of polydipsia and skin inflammation around the 
mouth. On long-term administration, dysphonia, hoarseness and voice fatigue were noted due 
to dysfunction of the innermost laryngeal muscles, particularly the vocal fold adductors. They 
concluded that long-term treatment with ICS resulted in myopathy of proper muscles of the 
larynx. 
Dogan, Eryuksel, Kocak and Sehitoglu (2007) performed a comparative, controlled, 
cross sectional study to evaluate the voice quality in patients with mild to moderate asthma 
using subjective and objective methods. Patients with mild to moderate asthma (n=40) were 
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age and sex-matched with a group of healthy controls (n=40). Acoustic analysis of jitter and 
shimmer was performed and the movements of the vocal cords were examined by 
videostroboscopy. In addition, the duration of asthma, maximum phonation time and vital 
(respiratory) capacity were evaluated. The Voice Handicap Index (VHI) scale was used for 
subjective evaluation of voice quality. The researchers found that maximum phonation time 
values were significantly shorter both in male and female patients with asthma compared to 
controls. Also the average shimmer values were higher for both sexes in the asthma group 
compared to the controls. Female patients with asthma had higher average jitter values 
compared to their healthy counterparts. The VHI score was outside the normative limits for 
patients with asthma (40%), and vital capacity findings were abnormal in 39 (97.5%) 
asthmatics. The researchers concluded that asthmatic patients demonstrated a generalized 
voice disorder compared to non-asthmatics. The outcome of the disorder was attributed to a 
laryngeal movement disorder and use of ICS. However, the authors could not exclude that 
some of the voice problems may have been caused by asthma. 
Gallivan et al. (2007) examined a total of 38 patients with voice complaints associated 
with the use of ICS. Hoarseness and dysphonia were the primary reasons reported in these 
patients. The ICS initially used most frequently was FP/salmeterol-inhalation powder (22 
patients), followed by FP inhalation aerosol pressurized MDI (11 patients) and five patients 
inhaled pulmicort (budesonide MDI). Duration of ICS usage varied from 2 weeks to 4-5 
years. Each patient’s vocal fold vibratory behaviour was examined using video-stroboscopy. 
They concluded that abnormalities in voice production previously unrecognized by indirect 
mirror or fibre optic laryngoscopy could be identified using a video strobe. These 
abnormalities included abnormal mucosal wave symmetry/periodicity (76-63%), phase 
closure (74-63%), glottic closure (63-59%), mucosal wave amplitude/magnitude (50-35%), 
supraglottic hyperactivity (39-25%) and glottic plane (10-5%). 
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Ishizuka et al. (2007) performed a simple observational study to evaluate 
hoarseness/dysphonia in patients with bronchial asthma who were using or had used the FP 
dry powder inhaler (DPI). A total of 313 patients with persistent bronchial asthma were 
evaluated. The patients were divided into three groups according to the daily dose of FP. A 
total of 109 patients had used a low dose of FP (100 or 200 µg/day), 145 patients were on a 
medium dose (300-400 µg/day) and 49 patients were on high dose of FP (600-800 µg/day). 
The researchers found that 25.9% of patients complained about local adverse effects, 
including throat discomfort, throat irritation, cough and hoarseness. A total of 20.4% of all 
patients complained of hoarseness/dysphonia. Moreover, most patients complained of local 
adverse effects within 6 months after starting FP-DPI therapy. Hoarseness/dysphonia was 
found more in the high-dose group (28.6%) as compared to the medium dose (17.9%) and 
low dose groups (20.2%). Female patients (30.3%) complained of hoarseness/dysphonia 
more frequently than their male counterparts (19.5%). 
The impact of ICS on the larynx and pharynx was assessed by Bhalla et al. (2009) 
using a prospective, cross-sectional and investigator blinded study. They recruited 46 
volunteers. The participations were divided into three groups 1) non-asthmatics 2) occasional 
ICS users or seasonal asthmatics and 3) regular ICS users. Laryngeal effects were measured 
by correlating the results of a vocal performance questionnaire, a respiratory symptoms 
questionnaire, and acoustic measurement of voice. The researchers concluded that regular 
ICS users demonstrated significantly more pharyngeal inflammation and throat discomfort 
than the other two groups. Laryngeal function and vocal performances were also worse in this 
group than the other two groups and were more likely to have hoarseness, weakness of voice, 
aphonia and cough. Results of acoustic analysis showed that the cycle-to-cycle variation in 
vocal F0 (i.e., jitter) was a good objective measure of hoarseness. Regular ICS users were 
also more likely to have abnormal amplitude variations in their F0 (i.e., shimmer). 
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Statement of the Problem 
The frequent use of ICS, especially at higher doses, has been accompanied by concern 
about side effects. Systemic side effects include lowering the number of mast cells in airway 
mucosa and a decrease in immediate response to allergen and exercise, muscle wasting, 
decrease in bone density (osteoporosis), glaucoma and cataracts, skin thinning, and bruising 
(Dahl, 2006). The use of ICS is also known to contribute to oral and oropharangeal 
candidiasis, cough during inhalation, tongue hypertrophy, and sensation of thirst (Hone et al., 
1996; Roland, Bhalla & Earis, 2004). A variety of studies have been undertaken to examine 
the effects of ICS on voice production among people with asthma. Most research suggests 
that the long-term use of ICS has a negative effect on voice production (Williams et al., 1983; 
Bhalla et al., 2009). These findings would suggest a trade-off between controlling the 
symptoms of asthma and maintaining normal vocal functioning. However, individuals with 
asthma present with a wide range of co-morbidity factors such as smoking, chronic cough 
and co-existing allergic rhinitis, which may confound the effects of ICS on voice production.  
One cannot exclude that some of the voice problems demonstrated by individuals with 
asthma is a result of their health condition rather than a consequence of using ICS.  
Furthermore, the type and dose of ICS has not been systematically controlled, thereby 
obscuring the direct effect of ICS on voice production. Interestingly, there is research to 
suggest that ICS may actually serve to improve voice production, if necessary precautions are 
taken in regard to control of dosage (Meyer et al., 2001). Normal voice production involves a 
combination of respiratory effort and vocal fold vibration. Because ICS is designed to 
improve respiratory functioning, it is possible that ICS could actually facilitate respiratory 
effort and concomitant vocal behaviour. Thus, it is not surprising to find reports (albeit 
limited) indicating that ICS may have a positive impact on voice production.  
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The recommended dosage of FP can range between 250 µg to 1000 µg per day (see 
Table 1). The most frequently prescribed daily dose of ICS in the Canterbury region of New 
Zealand is 1000 µg FP per day (Calverey et al., 2007). It seems that an ideal approach to 
examining the direct effects of ICS (FP) on voice production would be to exclude as many 
confounding factors as possible by recruiting healthy young adults without a history of 
smoking or respiratory illness including asthma, acute infection or allergic rhinitis. 
      The aim of the present study was to examine the isolated effects of ICS (fixed dose and 
type) on voice production in healthy adults. Based on audio-recorded voice samples collected 
before, during and after a short-term period of ICS use, the following research question was 
posed: 
Does an ICS (FP) have an effect on the acoustic features of voice production in 
healthy adults within a period of one week?  
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Table 1. Recommended daily dose of inhaled corticosteroid (FP) for adults with asthma, 
according to guidelines established by GINA (2008).  
 
      Drug Low Daily Dose (µg) Medium Daily Dose (µg) High Daily Dose (µg)  
FP 100- 250 250-500 500-1000 
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Method 
Participants 
Thirty healthy young adults (15 females & 15 males) were recruited for the study. All 
participants were non-smokers with no history of speech, language or voice disorder.  None 
of the participants had a history of asthma, respiratory illness, hospital admission or inhaler 
use within the past 3 months. The participants were recruited from the University of 
Canterbury student population. This study received ethical approval from the New Zealand 
Ministry of Health (Upper Southern B Health Ethics Committee), as well as the University of 
Canterbury Human Ethics Committee. The various consent forms and approvals granted for 
this study are listed in Appendix 2. 
Data Collection  
     The data collection for each participant occurred over a consecutive 6-day period. All data 
collection took place within a sound treated laboratory at the Department of Communication 
Disorders. The specific phases of data collection were as follows: 
Day 1 (Morning) 
       Audio Recording: On the morning of the first day of data collection, each participant’s 
voice was audio recorded.  The first sample was collected prior to inhalation of ICS and 
termed the Pre-ICS sample. This voice sample served as a baseline of normal vocal fold 
vibratory behavior which was to be compared to later recordings. Each participant was seated 
in front of a tabletop microphone that was placed at a distance of 20 cm from the mouth of 
the participant. The participant was asked to sustain the vowels /i/ (as in “he”), /a/ (as in 
“hah”) and /u/ (as in “who”) for five seconds each. Three samples of each vowel were 
collected. Upon completion of the vowel prolongation task, each participant was asked to 
read the Rainbow Passage (Fairbanks, 1960), which is a 100-word passage that is commonly 
25 
 
used in speech-language therapy to sample vocal behavior (listed in Appendix 2). All voice 
samples were audio recorded using a condenser microphone (DSE-PC) connected directly to 
a laptop computer. Each of audio recording session lasted approximately 10 minutes. 
       ICS Administration: Upon completion of the vocal tasks, the participant was asked to 
inhale a small amount of corticosteroid (FP). The participant was provided with a spacer 
attached to a MDI. The dose chosen was 500 µg of FP, which is the most prescribed FP dose 
in the Canterbury region of New Zealand. Prior to inhalation of FP, the participant was asked 
to exhale fully and place the mouthpiece of the spacer in their mouth.  The participant 
released 250 µg of FP into the spacing chamber by pressing the MDI once. When the 
chamber was filled with FP the participant was asked to take five tidal breaths so as to ensure 
inhalation of the steroid. This process was repeated so that the total dose administered was 
500 µg of FP. The participant was provided with cold water for rinsing his/her mouth upon 
completion of the ICS administration. All morning doses of FP were taken under supervision 
during the period of 9-10 a.m. 
         Audio Recording:  One hour after the morning ICS administration, each participant 
returned to the laboratory for a second audio recording of their voice.  The one-hour lapse 
between ICS and audio recording was deemed necessary so as to allow for the maximum 
effect of the steroid on the vocal apparatus. This recording was termed ICS-1. 
Day 1 (Evening) 
          Audio recording and ICS administration was carried out in the evening between the 
approximate hours of 4-6 pm. The first task involved ICS administration with the second task 
being the audio recording. 
       ICS Administration:  The identical procedures used in the morning were used in the 
evening session. In total, the participant was asked to inhale a 500 µg dose of FP.  
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       Audio Recording:  One hour after the evening ICS administration, each participant 
returned to the laboratory for a second audio recording of their voice.  The one-hour lapse 
between ICS and audio recording was deemed necessary so as to allow for the maximum 
effect of the steroid on the vocal apparatus. The same procedures used for the morning audio 
recording were used for the evening recording (i.e., vowel prolongations and oral reading of 
the Rainbow Passage). This recording was termed ICS-2. 
Days 2-4 
           On the second, third, and fourth days of the study, each participant received the same 
doses of FP during the morning and evening sessions. There were no audio recordings 
collected on these days.  
Day 5 (Morning & Evening) 
         On the morning of the fifth day of data collection, each participant received the same 
amount of FP similar to the previous four days. On the evening of the fifth day, audio 
recordings and ICS administration were carried out. The first task involved ICS 
administration with the second task being the audio recording. 
        ICS Administration:  The identical procedures used in the morning were used in the 
evening session. In total, the participant was asked to inhale a 500 µg dose of FP. 
        Audio Recording:  One hour after the evening session of ICS administration, each 
participant returned to the laboratory for another audio recording of their voice.  The same 
procedures used for the audio recordings collected on Day 1 were used for the evening 
recording on Day 5 (i.e., vowel prolongations and Rainbow Passage).  This recording was 
termed ICS-3. 
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Day 6 (Morning) 
            On the morning of the sixth day, only an audio recording of each participant’s voice 
was collected. This sample was termed Post-ICS and was used as a comparison to all 
previous samples to assess the cumulative effects of ICS administration over the 5-day 
period.  
Acoustic Analysis 
        Each participant’s audio-recorded samples were submitted to acoustic analysis using a 
commercially available speech analysis system (CSL 4300B, Kay Elemetrics, 1994). Three 
measures were performed:  
      (1) Vocal Fundamental Frequency (F0). Each vowel was displayed on a computer 
monitor as an amplitude-by-time waveform. The F0 of each vowel was determined by 
positioning a 50 ms window at the mid-point of each vowel. This section was then 
transformed into a power spectrum providing a cascading display of harmonics. A cursor was 
placed at the first harmonic peak of the display to determine F0. For each recording session, 
the second rendition of each repeated vowel production was measured. In total, one 
production of each of the three vowel (/i, u, a/) was measured for each recording session (Pre-
ICS, ICS-1, ICS-2, ICS-3 & Post-ICS).  
  (2) Formant Frequency and Formant Bandwidth. 
The first (F1) and second (F2) formant frequencies, as well as the first (BW1) and 
second (BW2) formant frequency bandwidth values were obtained for each sustained vowel. 
The F1 and F2 values provided information regarding the vocal resonance qualities of the 
vocal tract. The corresponding BW1 and BW2 measures provided information regarding the 
sound absorption qualities of the vocal tract (Rabiner & Schafer, 1978; Rothenberg, 1981). 
Measurement of these formant features was performed by examining the amplitude-by-time 
waveform and positioning a 50 ms time window at the approximate midpoint of each vowel. 
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This was the same location that was used for determination of vocal F0 for each vowel. The 
F1 and F2 values were obtained using linear predictive coding (LPC) autocorrelation analysis 
(36 coefficients). Bandwidths were computed automatically on the LPC spectrum by the CSL 
software and numeric results were provided in Hertz (Hz).  
   (3) Long-Time Spectral Analysis (LTAS). The LTAS analysis involved examining the 
spectral characteristics of one phrase of the Rainbow Passage, “The rainbow is a division of 
bright lights into many beautify colours.” Human voice production is assumed to reflect an 
interaction between a source (i.e., the vocal folds) and a filter. An LTAS analysis, limited to 
voiced sounds, can serve to average-out the effects of the filter, leaving a representation of 
the vibratory pattern of the vocal folds (Lofqvist & Mandersson, 1987). The amplitude-by-
time waveform of the entire Rainbow Passage was displayed on the computer monitor. A pair 
of vertical cursors was superimposed over the waveform to identify the above phrase. Based 
on this demarcation, an LTAS display was calculated through an averaging of individual Fast 
Fourier Transform (FFT) computations performed every 25 m/sec across the entire phrase. 
Once calculated, the LTAS data were stored as a file containing discrete frequency (Hz) 
values and the corresponding amplitude (dB) values. An example of a typical LTAS is shown 
in Figure 1. The following two measurements were performed using the LTAS file: 
First spectral peak (FSP). This is defined as the frequency value associated with the 
first amplitude occurring between a rising and subsequent falling amplitude value. The FSP is 
a representation of the average F0 across the sample (Lofqvist & Mandersson, 1987). 
Spectral tilt (ST). This is defined as the ratio of energy (sum of amplitudes) between 
0-1000 Hz, and 1000-5000 Hz. The ST is a representation of how quickly the amplitudes of 
the harmonics decline (Lofqvist & Mandersson, 1987). 
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Figure1.  Display of a typical long time average spectrum (LTAS) taken from Goberman and 
Robb (1999).  In this example, the location of the first spectral peak (FSP) is shown at 
approximately at 500 Hz. The general location of spectral tilt (ST) is also demarcated.  
Measurement Reliability 
Fifteen percent of the entire data base of vocal samples was randomly selected across 
10% of the participants for the assessment of intra-judge measurement reliability for the 
acoustic measurements (vocal F0, LTAS, formants/bandwidths, FSP & ST). A total of 6 
participants’ data was re-measured for F0, LTAS and formants/bandwidths. The original 
measurements were compared to the re-measurements. The average re-measurement 
difference for F0 was 34 and 12 Hz for females and males, respectively. The average re-
measurement difference for F1 was 24 and 14 Hz for females and males, respectively. The 
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average re-measurement difference for F2 was 76 and 58 Hz for females and males, 
respectively The average re-measurement difference for BW1 was 16 and 11 Hz for females 
and males, respectively The average re-measurement difference for BW2 was 35 and 29 Hz 
for females and males respectively The average re-measurement difference for FSP was 22 
and 12 Hz for females and males, respectively The average re-measurement difference for ST 
was 1.1 and 0.8 Hz for females and males, respectively. Collectively these re-measurements 
are within normal limits for acoustic measurement of voice in women and men (Kent, 1995). 
  Statistical Analysis 
A two-way repeated measures analysis of variance (ANOVA) served as the primary 
statistical procedure to evaluate possible changes in vocal behaviour across the five sampling 
sessions. The between-groups factor was sex and the within-groups factor was sampling 
session. Separate ANOVAs were performed for each acoustic measure.  
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Results 
F0    
     The results of the F0 analysis for male and female participants for each vowel type are 
listed in Table 2. As expected across all sampling periods the F0 of female voices was higher 
compared to male voices. Results of two-way repeated measures ANOVA for each vowel 
indicated a significant gender effect, [ /i/ F (1,28)= 49.46, p<.001;  /u/ F (1,28 ) = 52.14,  
p<.001 ; /a/ F (1,28) = 59.75, p<.001 ]. Across the three vowels there was no significant time 
and no significant time-by-gender interaction. 
F1 Frequency 
      The results of the F1 analysis for male and female participants for production of each 
vowel type are listed in Tables 3, 4 and 5, respectively across all sampling periods the F1 of 
female voices was higher compared to male voices. Results of a two-way ANOVA identified 
a significant gender effect for the vowels /i/ [F (1, 28) = 35.25, p<.001] and /a/ [F (1, 28) = 
35.84, p<.001]. There was no time-by-gender interaction for any of the vowel productions. 
However, there was a significant time effect for /i/ [F (1, 4) =2.85, p< .04].  Follow up t-tests 
identified a difference in F1 between Pre-ICS and ICS-1 (p = .033), as well as between ICS-1 
and ICS-2 (p = .046). The results for F1 /i/ are displayed in Figure 2. 
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Table 2. Mean (M) and standard deviation (S.D.) of the fundamental frequency (F0) in Hz 
for the vowels /i/, /u/ and /a/.  
 
Data are presented for both females and males across the five inhaled corticosteroids (ICS) 
sampling points. 
 
                           F0  /i/                                 F0  /u/                                F0 /a/ 
Female Pre 
ICS 
ICS.1 ICS.2 ICS.3 Post 
ICS 
Pre 
ICS 
ICS.1 ICS.2 ICS.3 Post 
ICS 
Pre 
ICS 
ICS.1 ICS.2 ICS.3 Post 
ICS 
Group 
M 
 
241.6 239.4 237 241.7 240.2 241.6 237.8 235.4 243.2 241 239.6 236.2 234.7 238.6 235.6 
S.D. 
 
41.7 40.2 49.2 48.7 51.8 41.7 37.6 50.3 49 48.4 43.5 35.8 51 50.3 45.7 
Males                
Group 
M 
152 152.7 143.4 152 157.4 156.2 151.9 142.6 148.8 147.3 148.8 144.9 139.4 152.7 141 
S.D. 
 
25.5 24.5 24.5 26.7 31.2 40.4 29 18.4 23.5 28.5 27 24.1 18.7 28.9 18.6 
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Table 3.  Mean (M) and standard deviation (S.D.) of the first (F1) and second (F2) formant 
frequency in Hz for the vowel /i/.  
                           F1  /i/                                       F2  /i/    
Female PreICS ICS.1 ICS.2 ICS.3 PostICS PreICS  ICS.1 ICS.2 ICS.3 PostICS 
Group 
M 
323.7 316.4 332.8 326.7 333.7 2542.0 2552.9 2579.1 2557.
2 
2574.2 
S.D. 41.8 44.1 46.1 38.5 43.8 529.6 421.3 379.7 457.0 514.3 
Male           
Group 
M 
248.8 241.2 272.4 249.7 250.6 2310.4 2373.6 2270.2 2364.
1 
2362.6 
S.D. 31.1 28.3 82.2 28.5 27.8 144.9 153.3 330.2 140.1 178.5 
Data are presented for both females and males across the five inhaled corticosteroid (ICS) 
sampling points. 
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Table 4.  Mean (M) and standard deviation (S.D.) of the first (F1) and second (F2) formant 
frequency in Hz for the vowel /u/.  
                           F1 /u/                                        F2 /u/  
Female PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
PreICS  ICS.1 ICS.2 ICS.3 Post 
ICS 
Group 
M 
344.7 329.3 345.2 344.4 335.9 1121.8 1091.9 1087.7 1162.6 1131.5 
S.D. 55.8 47.2 48.9 45.4 95.6 218.1 209.9 199.7 253.5 234.7 
Male           
Group 
M 
346.7 288.7 320.6 354.3 314.3 1092.2 1067.2 988.8 1049.3 1207.7 
S.D. 180.7 63.8 123.9 181.1 41.4 545.8 582.8 382.7 590.4 664.6 
Data are presented for both females and males across the five inhaled corticosteroid (ICS) 
sampling points. 
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Table 5.  Mean (M) and standard deviation (S.D.) of the first (F1) and second (F2) formant 
frequency in Hz for the vowel /a/.  
                           F1 /a/                           F2  /a/ 
Female PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
PreICS  ICS.1 ICS.2 ICS.3 Post 
ICS 
Group 
M 
809.6 804.6 858.5 836.5 820.4 1498.6 1465.7 1498.6 1484.4 1458.5 
S.D. 114.9 165.6 122.3 128.6 149.2 125.8 111.7 136.5 136.1 124.1 
Male           
Group 
M 
577.7 582.2 528.9 614.8 587.1 1175.8 1152.4 1185.5 1195.8 1182 
S.D. 143.6 109.9 149.2 155.7 147.4 95.4 120 80.4 95 141.1 
Data are presented for both females and males across the five inhaled corticosteroid (ICS) 
sampling points. 
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Table 6.  Mean (M) and standard deviation (S.D.) of the first (BW1) and second (BW2) 
bandwidth for the vowel /i/.  
                           BW1 /i/                                BW2  /i/ 
Female PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
Group 
M 
73.9 75.0 87.8 83.4 94.8 276.8 250.1 356.3 437.8 253.9 
S.D. 
 
36.4 43.4 37.3 44.4 81.3 218.6 197.9 366.1 717.7 164.4 
Male           
Group 
M 
58.9 67.0 79.6 78.2 78.7 214.8 203.8 382.4 213.8 229.2 
S.D. 
 
39.9 56.2 137.5 40.5 52.9 132.5 96.4 480.3 152.4 203.3 
Data are presented for both females and males across the five inhaled corticosteroid (ICS) 
sampling points. 
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Figure 2.  Display of first formant frequency of the vowel /i/ across the five inhaled 
corticosteroid (ICS) sampling periods. 
 
 
F2 Frequency 
     The results of the F2 analysis for male and female participants for each vowel type are 
listed in Tables 3, 4 and 5, respectively. Across all sampling periods, the F2 of female voices 
was higher compared to male voices. Results of a two-way ANOVA identified a significant 
gender effect for the vowel /i/ [F (1, 28) = 5.45, p = .027] and /a/ [F (1, 28) = 71.9, p <.001]. 
There was no significant time effect or time-by-gender interaction for any of the vowel 
productions. 
BW1 
     The results of the BW1 analysis for male and female participants for each vowel type are 
listed in Tables 6, 7, and 8, respectively. Across all sampling periods, the BW1 of female 
voices was higher compared to male voices for the vowel /i/ and /a/. However, the BW1 
value for the vowel /u/ was higher for male voices in comparison to female voices across all 
sampling periods. Results of a two-way ANOVA identified a significant gender effect for /u/ 
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[F (1, 28) = 5.38, p =.028]. There was no significant time effect or time-by-gender interaction 
for any of the vowel productions. The results for BW1 /u/ are shown in Figure 3. 
Figure 3.  Display of first formant frequency bandwidth for the vowel /u/ across the five 
inhaled corticosteroid (ICS) sampling periods. 
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Table 7.  Mean (M) and standard deviation (S.D.) of the first (BW1) and second (BW2) 
bandwidth for the vowel /u/.  
                           BW1 /u/                                       BW2 /u/ 
Female PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
Group 
M 
118.2 98.0 86.2 137.5 81.8 338.2 225.7 297.3 181.0 275.5 
S.D. 88.5 45.7 38.9 250.5 60.9 394.4 254.4 338.6 184.0 305.3 
Male           
Group 
M 
192.4 198.7 160.3 186.6 163.9 636.2 450.2 548.2 401.2 447.8 
S.D. 135.1 155.0 120.2 161.4 93.4 651.1 295.3 409.3 246.1 459.5 
Data are presented for both females and males across the five inhaled corticosteroid (ICS) 
sampling points. 
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Table 8.  Mean (M) and standard deviation (S.D.) of the first (BW1) and second (BW2) 
bandwidth for the vowel /a/.  
                           BW1 /a/                                       BW2  /a/ 
Female PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
PreICS ICS.1 ICS.2 ICS.3 Post 
ICS 
Group 
M 
231.4 314.4 231.3 242.2 278.8 192.3 196.7 276.4 215.3 228.9 
S.D. 
 
192.2 206.9 130.0 102.5 200.0 142.5 131.1 212.8 129.7 156.2 
Male           
Group 
M 
353.9 328.6 343.2 314.0 388.1 177.0 218.1 232.9 214.0 204.4 
S.D. 
 
188.9 144.3 222.9 212.0 318.5 107.4 193.9 190.1 120.7 126.1 
Data are presented for both females and males across the five inhaled corticosteroid (ICS) 
sampling points. 
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BW2 
      The results of the BW2 analysis for male and female participants for each vowel type are 
listed in Tables 6, 7, and 8, respectively. Across all sampling periods, the BW2 of female 
voices was higher compared to male voices for the vowel /i/ and /a/. However, the BW2 
value for the vowel /u/ was higher for male voices in comparison to female voices across all 
sampling periods. Results of a two-way ANOVA identified a significant gender effect for /u/ 
[F (1, 28) = 5.17, p = .031]. There was no significant time effect or time-by-gender 
interaction for any of the vowel productions. The results for BW2 /u/ are shown in Figure 4. 
Figure 4.  Display of second formant frequency bandwidth for the vowel /u/ across the five 
inhaled corticosteroid (ICS) sampling periods. 
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FSP 
 
     The results of the FSP analysis for male and female participants for each rendition of the 
Rainbow Passage are listed in Table 9. The FSP of female voices was higher compared to 
male voices across all sampling periods. Results of a two-way ANOVA identified a 
significant gender effect for FSP [F (1, 28) = 26.29, p <.001]. The effects of time on FSP 
approached significance [F (1, 4) = 2.61, p=.06]. Follow up t-tests identified a significant 
difference in FSP between ICS 2 and ICS 3, (p =.024). There was no significant time-by-
gender interaction. The results for FSP analysis are displayed in Figure 5. 
Figure 5.  Display of combined mean first spectral peak (FSP) of males and females across 
the inhaled corticosteroid (ICS) sampling periods. 
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ST 
       The results of the ST analysis for male and female participants for each speech sample 
are listed in Table 10. Results of a two-way ANOVA identified a significant time effect for 
ST [F (1, 4) =3.5, p=.02]. Follow up t-tests identified a significant difference in ST between 
Pre-ICS and ICS-1, (p = .034), as well as between ICS-2 and ICS-3, (p =.033). There was no 
any significant gender effect or time-by-gender interaction. The results for ST are displayed 
in Figure 6. 
Figure 6. Display of combined mean spectral tilt (ST) of males and females across the five 
inhaled corticosteroid (ICS) sampling periods. 
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Table 9. Long-time average spectrum (LTAS) characteristics for groups of adult females and 
males.  
                                                                  FSP  
Females Pre ICS ICS.1 ICS.2  ICS.3 Post ICS 
Group M 205.1 193.2 200.2 217.4 211.7 
S.D. 
 
44.4 40.5 43.1 42.6 43.5 
Males      
Group M 134.3 144.4 127.4 150.6 138.3 
S.D. 38.5 47.2 40.5 53.0 49.7 
The table contains the average first spectral peak (FSP) and the mean (M) and standard 
deviation (S.D) derived across five inhaled corticosteroid (ICS) sampling points. 
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Table 10. Long-time average spectrum (LTAS) characteristics for groups of adult females 
and males.  
ST 
Females Pre ICS ICS.1 ICS.2  ICS.3 Post ICS 
Group M 4.0 3.2 3.9 2.4 3.1 
S.D. 2.4 1.6 2.3 1.5 1.3 
Males      
Group M 
 
4.0 3.0 2.7 2.4 3.1 
S.D. 3.1 2.2 1.8 2.0 2.5 
The table contains the average spectral tilt (ST) and the mean (M) and standard deviation 
(S.D) derived across five inhaled corticosteroid (ICS) sampling points sampling points. 
ST is expressed as the following: ∑ dB0-1000 Hz / ∑ dB1-5000 Hz. 
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Summary of Major Findings 
1. The F0 values for females were higher in comparison to males across all sampling periods. 
In addition there was no significant change in F0 across the sampling intervals. 
 2. The F1 frequency values for females were higher in comparison to males across all 
sampling periods. There was a significant time effect for the vowel /i/ with the F1 frequency 
at ICS-1 being significantly lowered compared to the Pre-ICS and ICS-2 sampling points.  
3. The F2 values for females were higher in comparison to males across all sampling periods.   
There was no significant change in F2 across sampling intervals.  
4. Across all sampling periods, the BW1 and BW2 of female voices was higher compared to 
male voices for the vowels /i/ and /a/. However, the BW1 and BW2 values for the vowel /u/ 
were higher for males in comparison to females across all sampling periods. There were no  
significant changes in BW1 or BW2 across the sampling intervals. 
5. The FSP of female voices was higher compared to male voices across all sampling periods. 
Results revealed that there was a significant time effect for FSP for the combined groups. The 
FSP values increased significantly on day five (ICS 3) after the inhalation of ICS in 
comparison to day one (ICS 2). 
6. The ST values across all sampling periods revealed no significant gender effect. For the 
combined group of females and males, the ST values decreased after the inhalation of ICS in 
the morning of day one (ICS-1) in comparison to Pre-ICS. Also the ST values significantly 
decreased at ICS-3 in comparison to ICS-2. 
 
 
47 
 
Discussion 
Corticosteroids are the most potent and reliable of the available agents among the 
anti-inflammatory drugs, and have assumed a major role in the management of asthma 
(Szelfler, 1991). This has subsequently resulted in the widespread use of ICS. The impact of 
ICS on voice production has received considerable research attention. Some of the research in 
this field implicates ICS in the development of dysphonia (Williams et al., 1983; Bhalla et al., 
2009). However, many studies have the weaknesses of including an asthmatic population and 
not consistently recording the dose prescribed. As a result, one cannot exclude that some 
voice problems may have simply been caused by asthma rather than use of an ICS (Meyer et 
al., 2001). Keeping this in mind, the purpose of the present study was to examine the effects 
of ICS using a fixed dose and type on voice production in healthy adults. The research 
question posed for this study was:   
Does an ICS (FP) have an effect on the acoustic features of voice production in 
healthy adults within a period of one week?   
 
Vocal F0 
Fundamental frequency (F0) is defined as the lowest frequency component of a 
complex periodic sound (Borden, Harris & Raphael, 1994). When describing the F0 of 
the human voice, the term refers to the rate of vocal fold vibration. The average F0 of an 
adult male voice is approximately 125 Hz, while women phonate with an F0 of 
approximately 200 Hz.  Children have an F0 in excess of 300 Hz (Borden et al., 1994). 
The length, size, and stiffness of the thyroarytenoid muscle (i.e., vocal folds) are the 
primary contributing factors to F0. Typically, men have larger vocal folds than women, 
with children having the smallest vocal folds, thereby explaining the often cited 
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differences in F0 between these speaker groups (Baken & Orlikoff, 2000; Guimaraes & 
Abberton, 2005; Sussman & Sapienza, 1994).  
Results of the present F0 analysis indicated there was a sex difference for the F0 of 
each vowel type across the five sampling points, with females showing a significantly 
higher F0 than men. There was no change in F0 across time, indicating that the use of ICS 
did not appear to affect the average rate of vocal fold vibration. Three possibilities for the 
lack of change in F0 across time are presented. First, it is possible that the lack of change 
in F0 is a result of the speech samples measured in the present study. The F0 analysis was 
confined to isolated vowel production. Use of a larger and more natural speech sample, 
such as conversational speech, may have provided a more revealing influence of ICS on 
vocal fold vibrations. A second possibility for the lack of change in F0 across the 
sampling periods is to consider the pharmacology of ICS. The inhalation of 
corticosteroids is designed to serve as an anti-inflammatory agent (Barnes, 2001). 
However, among the present group of participants there was no pre-existing inflammation 
of the vocal folds, so it is possible the corticosteroid had no direct affect on the vocal fold 
musculature (i.e., no change in F0). Finally, it is important to note that past studies which 
have found a change in F0 have attributed this change to the irritating affects of ICS 
(Roland et al., 2004). This irritation results from the use of propellant and lubricant 
components of MDI preparations. These “residue” components, when inhaled, irritate the 
pharyngolaryngeal mucosa. However, in the present study this irritation did not appear to 
affect average vocal fold vibration (i.e., F0), most likely due to short-term use of ICS.   
 
F1 and F2 Frequency 
The resonances of the vocal tract are referred as formants. A formant is an acoustic 
feature which is associated with a peak in the acoustic spectrum that is shaped by the 
configuration of the vocal tract (Borden et al., 1994). The F1 frequency represents vocal 
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tract resonance occurring at the pharyngeal level (Kent, 1995). The F1 frequency depends 
on the volume of the pharyngeal cavity, as well as how tightly the vocal tract is 
constricted (Ferrand, 2001). The F2 frequency represents vocal tract resonance occurring 
at a more superior level, within the general region of the oro-pharynx. The F2 frequency 
depends on the length of the oral tract. These volumes (and corresponding formant 
frequency values) can be changed by altering tongue positioning. 
Results of the present F1 analysis indicated there was a significant time effect for 
production of the vowel /i/. Specifically, F1 frequency was found to lower between pre-
ICS and ICS-1 sampling points; with a rise in F1 between ICS-1 and ICS-2. The F1 
frequency at ICS-1 was the lowest frequency value observed across the five sampling 
points. Interestingly, the unusually low F1 frequency at ICS-1 was the point at which each 
participant received their first dose of ICS. The low F1 frequency would suggest that the 
volume of the pharyngeal cavity was enlarged compared to the sampling periods before 
and after ICS-1. This enlargement can occur in two-ways. First, the length of the vocal 
tract can be increased by either moving the tongue forward in the vocal tract and/or 
lowering of the larynx.  A second possibility for the increased volume is that the diameter 
of the vocal tract area increased. Assuming, ICS serves as a bronchodilator, it is 
intriguing to consider that the dilating effects of this steroid could also influence the 
volume of the pharyngeal cavity, resulting in an increase of vocal tract area (i.e., lowering 
of F1 frequency).  
A sex difference was also found for the production of each vowel. The F1 and F2 
frequency of each vowel was higher for females compared to males, with significant 
differences noted for the vowels /i/ and /a/. This sex difference is not surprising. Past research 
has consistently shown that the formant frequencies of the female voice are higher compared 
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to the male voice, as a result of smaller female vocal tract anatomy (Borden et al., 1994; 
Kent, 2001). 
Formant Frequency Bandwidth (BW1 & BW2) 
Bandwidth is defined as a measure of frequency band of a sound especially a 
resonance. Conventionally, bandwidth is determined at the half power (“3 dB down”) points 
of the frequency response curve. That is, both the lower and higher frequencies that define 
the bandwidths are 3 dB less intense than the peak energy in the band (Kent, 1995). The 
bandwidths of the lowest formant depend upon vocal tract wall loss and source-tract 
interaction (Rabiner & Schafer, 1978; Rothenberg, 1981). Bandwidths of the higher formants 
depend primarily upon the viscous friction, thermal loss, and radiation loss. These factors 
may differ between genders leading to gender differences in bandwidths and overall spectral 
shape (Flanagan, 1972). 
  In the present study, across all sampling periods, the BW1 and BW2 of female voices 
was larger compared to male voices for the vowels /i/ and /a/. However, the BW1 and BW2 
values for the vowel /u/ were larger for males in comparison to females across all sampling 
periods. There were no significant changes in BW1 and BW2 across the sampling intervals. 
Past research has shown that females have larger formant frequency bandwidths compared to 
males (Bladon, 1983). The main reason for females having larger bandwidths can be 
primarily attributed to the vocal tract wall loss and source-trace interactions noted above 
(Rothenberg, 1981). The larger formant bandwidths noted for male production of /u/ was 
unexpected and suggests that there may be vowel-specific differences between men and 
women in regard to formant bandwidths.  
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Long Time Average Spectra (LTAS) 
First Spectral Peak (FP) is defined as the frequency value (in Hz) associated with the 
first amplitude peak across the LTAS display. The first spectral peak is assumed to provide a 
representation of the average F0 across the phonatory sample (Fuller & Horii, 1988). Any 
upward or downward change in the frequency of the spectral peak would reflect 
corresponding increases or decreases in sub-glottal pressure and vocal fold stiffness. 
FSP was used in present study as a way of estimating F0 in a connected speech 
sample (i.e., the Rainbow Passage). Across all sampling periods, women had a higher FSP 
than males, which corresponds to the F0 results obtained from isolated vowel productions. It 
is difficult to compare the present results to past studies examining ICS because they have not 
used LTAS. However, past ICS studies have examined F0. The present results obtained for 
FSP supports past F0 studies that have found a higher F0 values for females compared to 
males. The primary reason for the sex difference is attributed to laryngeal size differences 
(Childers & Wu, 1991; Sussman & Sapienza, 1994; Whalen & Levitt, 1995; Baken & 
Orlikoff, 2000; Torre & Barlow, 2009). 
An interesting finding in the present study was that for the combined groups, FSP was 
found to significantly change across ICS sampling intervals. Specifically, FSP increased 
between the evening of day one (ICS-2) compared to the recording on the evening of day 5 
(ICS-3). In the present study changes in FSP were evident in the running speech sample; 
however no such changes and were detected in isolated vowels based on measurement of F0. 
The likely reason for these discrepant findings is due to the amount of speech being sampled 
to estimated average vocal fold vibration. Based on measuring a large sample of speech, a 
significant change in vocal fold vibratory behaviour was evident during the course of ICS 
use. The increase in FSP at ICS-2 is in agreement with past studies which attributed the 
increase in F0 to the irritating effects of corticosteroids (Watts, Clark & Early, 2001). Thus, 
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the present findings would appear to suggest that the effects of ICS use were more evident in 
connected speech samples compared to production of isolated vowels.   
Spectral Tilt (ST) is defined as the ratio of energy (sum of amplitudes) between 0 and 
1000 Hz, and 1000 and 5000 Hz. The ST is a representation of how quickly the amplitudes of 
the harmonics decline (Lofqvist & Mandersson, 1987). Past research among adults has shown 
that a high ST value corresponds to hypoadduction of the vocal folds, whereas a low ST 
value corresponds to a hyperadduction of the vocal folds (Mendoza, Munoz, & Naranjo, 
1996). 
In the present study, ST was measured using connected speech from the Rainbow 
Passage (Fairbanks, 1960). ST was found to be significantly lower following use of ICS in 
the morning of day one (ICS-1) in comparison to Pre-ICS. The ST was also significantly 
lower at ICS-3 in comparison to ICS-2. These significantly lower ST values are suggestive of 
hyperadduction of the vocal folds. Similar to the results obtained from FSP, the effects of ICS 
were evident in connected speech samples. Based on the combined results for FSP and ST it 
would appear that use of ICS contributed to an overall hyperfunctional voice at distinct points 
across the one-week period of the study.  
Limitations 
     Results of the present study found changes in some, but not all of the acoustic measures of 
voice as a function of ICS sampling and/or sex. These changes were confined to LTAS 
measures of connected speech. When considering these results, it is important to recognize 
some possible limitations in the present study. Examples of these limitations are provided 
below.   
1. In the present study, some of the participants’ first language was not English. As a 
result of accent/dialect differences in the articulation of speech it is possible that these 
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speaker differences could have contributed to variations in the acoustic measures. 
However, it is important to stress the present set of acoustic measures were designed 
primarily to assess vocal fold vibratory characteristics (e.g., F0, FSP, ST). Therefore, 
the influence of language differences on these measures is likely to be minimal.   
2. The present study did not involve perceptual evaluation of voice across the duration 
of sampling periods. By having the participants self evaluate their voice, possible 
changes in voice resulting from ICS use may have been detected that were not 
detected using acoustic analysis.  
3. The present study was exploratory by only examining the short term effects of ICS on 
voice production. The one-week sampling used in the present study may have been 
too short to determine the major influences of ICS on voice production. Still, it is 
noteworthy that in spite of the short timeframe of sampling, ICS effects of voice 
production were evident.   
4. Each of the participants was asked to prolong vowels and read the Rainbow Passage 
(Fairbanks, 1960). The researcher provided a model to each participant in regard to 
the prolongation of vowels. For the oral reading of the Rainbow Passage, each 
participant was simply asked to read the passage at their normal speaking rate. By not 
controlling for the speaking rate of the Rainbow Passage, it is possible that the 
acoustic results measured in this passage (i.e., FSP, ST) could have been affected. 
Past research has shown that alterations in speaking rate (fast or slow) can have an 
influence on the subsequent acoustic features of speech production (Kent, 2001). 
While each participant was judged by the researcher to read the passage at a normal 
speaking rate, the precise rate of speaking was not measured. Thus, one cannot rule 
out the possibility that rate differences had an influence in the present results.  
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Clinical Implications 
      Past research examining the acoustic effects of voice resulting from ICS have focused 
primarily on patients with asthma. Most research indicates that the long-term use of ICS has a 
negative effect on voice production (Williams et al., 1983; Lavy et al., 2000 & Bhalla et al., 
2009). These findings would suggest a trade-off between controlling the symptoms of asthma 
and maintaining normal vocal functioning. However, individuals with asthma present with a 
wide range of co-morbidity factors such as smoking, chronic cough and co-existing allergic 
rhinitis, which may confound the effects of ICS on voice production. In the present study, 
these co-morbidity factors were controlled by examining healthy non-asthmatic men and 
women. On the basis of using the recommended dosage of 1000 µg FP per day (Calverey et 
al., (2007), effects on voice production were evident within one-week of ICS usage. These 
results suggest that the short term use of ICS is associated with negative effects on voice 
production. However, the negative changes in voice reversed to normalcy within one day of 
discontinuation of ICS use (i.e., at Post-ICS). From these present results, it seems clear that 
caution is warranted when prescribing ICS for individuals with asthma. While short-term use 
is likely to have minimal long-lasting effects on voice production; long term effects may 
result in significant damage to the voice. 
 
Directions for Future Research 
In the present study it was observed that some acoustic features of voice production 
changed during the period of ICS use. However, these same acoustic features were found to 
return to their Pre-ICS values after discontinuing ICS. This pattern of change would seem to 
indicate that the irritating effects of short term ICS on vocal fold vibratory behavior are 
temporary. A logical next step in this line of research would be to determine whether the 
effects are temporary or long lasting by examining ICS use over a longer time period. A 
secondary area of research could be to determine the effects of various doses of ICS on voice 
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production. The present study used a well established dose of 1000 µg/day. However, it is not 
unusual to find doses ranging from 200 µg/day to 2000 µg/day (Humbert et al., 2008). 
Presumably, ICS use at a lower dose would have a less severe impact on voice production 
compared to higher doses of ICS. However, it is possible that low doses such as 200 µg/day 
may have the same effects as larger doses.  Finally, a continuation of this study would be to 
examine the perceptual voice characteristics of the present group of participants. While 
acoustic changes were evident at various points in the ICS regime, no attempts were made to 
determine whether these acoustic changes were perceptible. 
  
Conclusion 
      In summary the purpose of the present study was to examine the short term effects of ICS 
(FP) on acoustic features of voice production. The general question was to determine whether 
ICS has an effect on acoustic features of voice following short term exposure to ICS. The 
results of this study indicate that ICS does have an effect on acoustic properties of voice. 
These effects were more evident in connected speech compared to isolated vowel 
productions. 
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Appendix 1 
Undesirable effects of FP and treatment as specified by the New Zealand Medicines and 
Medical Devices Safety Authority (MEDSAFE) 
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Home  Health Professionals   | Search 
FP propionate Inhaler (CFC-Free) (50, 125 or 250 micrograms per actuation). 
Overdose. Acute inhalation of FP doses in excess of those recommended may lead to 
temporary suppression of adrenal function. This does not need emergency action as adrenal 
function is recovered in a few days, as verified by plasma cortisol measurements. 
Undesirable Effects. Candidiasis of the mouth and throat (thrush) of voice occurs in some 
patients, such patients may find it helpful to rinse out their mouth with water after using the 
inhaler. Symptomatic candidiasis can be treated with topical anti-fungal. In some patients, FP 
may cause hoarseness or throat irritation. It may be helpful to rinse out the mouth with water 
immediately after inhalation. The use of a large volume 'spacer' device may be considered. 
There may be contusion on skin in some patients. Systemic effects may occur with any 
inhaled corticosteroid, particularly at high doses prescribed for long periods. 
Preclinical Safety Data. Preclinical safety studies indicate that FP shows negligible systemic 
toxicity when administered by the inhaled route. FP propionate is devoid of mutagenic 
activity in-vitro and in-vivo and showed no tumorigenic potential in rodents. It is both non-
irritant and non-sensitising in animal models.The non-CFC propellant, HFA 134a, has been 
shown to have no toxic effect at very high vapour concentrations. 
Contra-indications. FP Inhaler is contra-indicated in patients with a history of 
hypersensitivity to any of its components. 
Effects on Ability to Drive and Use Machines. FP propionate is unlikely to produce an 
effect on driving or operating machines. 
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Ref:  HEC 2009/102  
 
 
 
12 August 2009  
 
 
Ramesh Sahrawat 
Health Sciences Centre 
UNIVERSITY OF CANTERBURY 
 
 
Dear Ramesh  
 
The Human Ethics Committee advises that your research proposal “Influence of inhaled 
corticosteroids on acoustic features of normal voice production in adults” has been considered 
and approved.   
 
Please note that this approval is subject to the incorporation of the amendments you have 
provided in your email of 11 August 2009. 
 
Best wishes for your project. 
 
 
Yours sincerely 
 
 
 
 
 
Dr Michael Grimshaw 
Chair, Human Ethics Committee 
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The Department of Communication Disorders is looking for participants 
for a study entitled: 
 
Studying the Effects of Inhaled 
Corticosteroids on 
Normal Voice Production in Adults  
 
 
We are looking for healthy adult females between the 
ages of  
18-21 years  
 
This study will take place at the Department of Communication 
Disorders Research Laboratory  
University of Canterbury Campus 
19 Creyke Road, Christchurch 
 
Each session will take approximately 15 minutes of your time 
every morning (9-10am) and evening (4-5pm) for a 5-day period. 
 
You may be provided with two Hoyts movie passes at the end of 
your participation. 
 
 
 
Research Participants Needed 
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 If you are interested and would like more information, please contact 
 
Prof. Michael Robb                                                    Ramesh Sahrawat 
   Phone: 03 3642987 Etxn :7077                                    Phone: 03 3557980 
   Mobile: 021 0630311                                Mobile: 021 1816115 
   michael.robb@canterbury.ac.nz                            rsa61@student.canterbury.ac.nz         
 
 
 
This project has been reviewed and approved by Upper Southern Health Ethics  
Committee and the University of Canterbury Human Ethics Committee. 
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INFORMATION SHEET 
 
Studying effects of inhaled corticosteroids on normal voice production in adults. 
 
Principal Investigator: 
 
Prof. Michael Robb  
Department of Communication Disorders 
University of Canterbury 
Christchurch NZ 
Phone: 03 3642987 Extn: 7077 
 
Co-Investigators: 
Ramesh Sahrawat     Dr Lutz Beckert MD, MRCP         Prof Ray Kirk, (Director).  
Department of Health Sciences.    Department of Medicine.         Department of Health Sciences. 
University of Canterbury    University of Otago          University of Canterbury 
Christchurch NZ                            Christchurch NZ                      Christchurch NZ 
Phone: 03 3557980                        Phone: 03 3640640 Phone: 03 3643108 
 
Introduction and aims of the project: 
You are invited to participate in a research project investigating the influence of inhaled corticosteroid 
(Fluticasone) on normal voice production. This study will contribute to completion of Master’s of 
Health Science Degree. This study will gather information whether inhaled corticosteroids (ICS) have 
immediate or delayed side effects on voice production. As research, so far carried out is on people 
with asthma and other respiratory conditions. This is an exploratory research to find the effects of ICS 
on voice production in healthy adult females. This may become relevant in the management of 
individuals with asthma. 
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You have the right not to participate in the study, or subsequently withdraw from this study at 
any time. Any decision not to participate will not affect your current, continuing or future 
health care at this or any other health care facility, nor will it affect your academic progress 
through the university, if applicable. We would appreciate a decision regarding your 
participation within one week.  
 
Participants: 
You have been invited to attend a screening visit following your reply to our advertisements 
for research participants.  You may be selected for this study if you are judged to have no 
health problems that may affect your participation. The study will include a total of 20 
participants.  
 
Procedure: 
The research will take place at the University of Canterbury Communication Disorders 
Research Laboratory (Room 121) located at 19 Crekye Road. If you agree to participate in 
the study, the following will occur: 
 
1. You will be given a specific appointment to arrive at the Communication Disorders 
Research Laboratory.  Ample, free parking is located in front of the facility.  
 
2. You will be asked to complete a brief medical questionnaire to confirm that you meet 
the inclusion criteria for study participation.  
 
3. The exact procedures involved in this research project will be explained to you in 
detail. You will also have the opportunity to raise and discuss any questions with the 
investigator.  
 
4. If you agree to participate in the study, you will be given a consent form to sign. You 
will be assigned a participant number for identification of all subsequent data. If you 
wish you can have your whanau / family to be present during the study 
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. 
5. At the commencement of the study you will be seated in a chair directly facing the 
investigator. 
 
6. The investigator will provide you with a demonstration and directions about how to 
perform the two different vocal tasks: (1) sustaining three vowels /i/ (as in “he”), /a/ 
(as in “hah”) and /u/ (as in “who”) for 5 seconds each ( repeated 3 times), and reading 
aloud a 100 words passage. 
 
7.  After this instructional period, you will remain seated at a table. A tabletop 
microphone attached to a laptop computer will be kept at a distance of 20cm from 
your mouth and you will be asked to sustain each vowel and read the passage. These 
vocal samples will be recorded directly into the computer. 
 
8. Upon completion of the vocal tasks, you will be asked to inhale a small amount of 
corticosteroid known as FP. You will be provided with a spacer attached to a metered 
dose inhaler (Puffer).  The dose chosen is FP 500mcg, which is the most prescribed 
FP dose in Canterbury. 
 
9. Prior to inhalation of FP, you will first need to exhale all the air out of your lungs and 
put the mouthpiece of the spacer in your mouth. At this time, you will be asked to 
push the puffer once to release the FP 250 mcg into the spacing chamber. Once the 
chamber is filled with FP you will take several deep breaths (inhalations). This 
process will happen twice, so that the total dose administered will be FP 500 mcg. 
 
10. The same process of FP inhalation will be carried out in the afternoon (between 4-5 
pm). 
 
11. Another vocal sample of vowel prolongations and oral reading will take place 
approximately one hour following the evening dose of FP. 
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12. You will be asked to perform the same procedures of inhalation of FP in the morning 
(between 9-10 am) and evening (between 4-5 pm) for the next 4 days (total of five 
days). 
 
13. Each dose administration will take place at the Communication Disorders Research 
Laboratory and directly supervised by the investigators. 
 
14. Following the last dose of FP on the fifth day (evening sample), the third and final 
voice recording will be obtained. The vocal recording will involve the same vowels 
and oral reading passage. This recording will occur approximately one hour after the 
last dose of FP. 
 
The information gathered during the study will be stored for subsequent analysis. 
Confidentiality will be assured by assigning you a coded numerical identification. Data will 
be stored in the locked Communication Disorders Research Laboratory at the University of 
Canterbury. 
Risks or Benefits: 
There will be no direct benefit to you by participating in this research. Each participant will 
be provided with two movie passes to Hoyts Cinema. There may be some associated local 
side effects with short-term use of FP. These side effects include oral candidiasis (fungal 
infection in the mouth), oral thrush and feeling of thirst. Any local side effects associated 
with FP will resolve within two weeks of discontinuing the steroid. 
 
You will be monitored carefully by the investigators for any negative outcomes arising from 
your participation in this study. In the event of any adverse reactions to FP, Dr Lutz Beckert, 
Respiratory Physician Christchurch Hospital, will make time to assess you. Dr Beckert is one 
of the co-investigator of this study and has considerable clinical experience in prescribing and 
use (treating patients) of FP. He will be constantly involved throughout this study. In 
addition, your G.P can be notified upon receiving permission from you to do so. 
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Participation: 
Your participation is entirely voluntary. If you do agree to take part in this study, you are free 
to withdraw at any time, without having to give a reason. This will in no way affect any 
future care or treatment or your academic status if you are a University student.  
Your participation in the study will be stopped should any harmful effects appear as a result 
of inhaling FP. 
 
Confidentiality: 
The results of this study will be published in a peer reviewed journal and may also be 
presented at international conferences. However, no material which could personally identify 
you will be used in any reports on this study. With the exception of the consent form, all data 
will be identified using a number coding system. Thus, you will be identified only by a 
participant number and will not be referred to by name when identifying or discussing the 
data. Only those individuals directly associated with the project will have access to any data 
collected. All information associated with this project, including the consent form containing 
your name, will be kept in a locked filing cabinet within the Department of Communication 
Disorders, at the University of Canterbury. The data will be stored for a period of ten years, 
and then it will be destroyed. Written documents will be shredded. 
 
Results: 
Upon completion of this research, you will be offered both a copy of the final manuscript and 
a copy of the results in lay language. However, you should be aware that a significant delay 
may occur between completion of data collection and completion of the final report. 
Alternatively, or in addition, you can choose to have the results of the study discussed with 
your personally by the lead investigator.  
 
Questions 
You can contact one of the investigators or the research supervisor if you require any further 
information about the study.  
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The lead investigator, Prof. Michael Robb, can be contacted during work hours at (03) 364 
2987 Extn: 7077, or 021 0630311 or via email: michael.robb@canterbury.ac.nz 
The co-investigator, Ramesh Sahrawat, can be contacted during work hours (03) 3642987 
Etxn: 8691, or 021 1816115or via email: rsa61@student.canterbury.ac.nz 
The co-investigator, Dr Lutz Beckert, can be contacted during work hours (03) 3640640 or 
027 4677583 or via email: lutz.beckert@cdhb.govt.nz 
The co-investigator, Prof. Ray Kirk, can be contacted during work hours (03) 3643108 or 027 
2143338 or via email: ray.kirk@canterbury.ac.nz 
If you need an interpreter, this can and will be provided. 
If you have any queries or concerns about your rights as a participant in this study, you may 
wish to contact a Health and Disability Advocate, telephone: 
 South Island 0800 377 766  or (03) 377 7501 in Christchurch.  
 Free Fax (NZ wide): 0800 2787 7678 (08002SUPPORT)  
 Email (NZ wide):  advocacy@hdc.org.nz 
This study has received ethical approval from the Upper South B Regional Ethics Committee. 
Ethics Reference Number:  URB/09/07/027. 
 
This project has been reviewed and approved by Upper Southern Health Ethics 
Committee and the University of Canterbury Human Ethics Committee. 
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CONSENT FORM  
  STUDYING INFLUENCE OF INHALED CORTICOSTEROID ON NORMAL VOICE 
PRODUCTION IN HEALTHY ADULTS      
 
English 
 
I wish to have an interpreter. Yes No 
Maori 
 
E hiahia ana ahau ki tetahi kaiwhakamaori/kaiwhaka 
pakeha korero. 
Ae Kao 
Samoan 
 
Oute mana’o ia iai se fa’amatala upu. Ioe Leai 
Tongan 
 
Oku ou fiema’u ha fakatonulea. Io Ikai 
Cook 
Island 
 
Ka inangaro au i  tetai tangata uri reo. Ae Kare 
Niuean 
 
Fia manako au ke fakaaoga e taha tagata 
fakahokohoko kupu. 
E Nakai 
 
 
I have read and I understand the Information Sheet dated 01/05/2009 for volunteers taking part 
in the study designed to investigate the effects of inhaled corticosteroid (Fluticasone) on 
normal voice production. I have had the opportunity to discuss this study.  I am satisfied with 
the answers I have been given. 
 
I have had this project explained to me by_____________________________. 
 
I understand that taking part in this study is voluntary (my choice) and that I may withdraw 
from the study at any time and this will in no way affect my current, continuing or future health 
care. I understand that if I choose to withdraw from the study, I may also withdraw all 
information that I have provided.  
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I understand that the information obtained from this research may be published. However, I 
understand that my participation in this study is confidential and that no material which could 
identify me will be used in any reports on this study.  
 
I understand that the investigation will be stopped if it should appear harmful to me and I 
know whom to contact if I have any side effects to the study or have any questions about the 
study. 
 
I understand the potential risks of participation in the study as explained to me by the 
researcher. 
 
I understand the compensation provisions for this study.  
 
I have had time to consider whether to take part. 
 
I wish to receive a copy of the results.       
YES / NO 
 
* Please note that a significant delay may occur between data collection and publication of 
the results 
 
I would like the researcher to discuss the outcomes of the study with me 
YES / NO 
 
I wish that my whanau / family to be present during the study. 
YES / NO 
 
I, ____________________________ hereby consent to take part in this study.   
 
I wish to consent that the data collected from this study may be used for further research 
YES / NO 
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Signature_____________________________________Date____________________ 
Signature of researcher_____________________  
Name of researcher________________________ 
 
 
Name of primary researcher and contact phone numbers: 
Prof. Michael Robb     
Work ph.  03 364 2987 ext 7077    
Mobile: 0210630311 
 
(Note: A copy of the consent form to be retained by participant) 
 
 
This project has been reviewed and approved by Upper Southern Health Ethics 
    Committee and the University of Canterbury Human Ethics Committee. 
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The Rainbow Passage 
When the sunlight strikes raindrops in the air, they act as a prism and form a rainbow. The 
rainbow is a division of white light into many beautiful colours. These take the shape of a 
long round arch, with its path high above, and its two ends apparently beyond the horizon. 
There is, according to legend, a boiling pot of gold at one end. People look, but no one ever 
finds it. When a man looks for something beyond his reach, his friends say he is looking for 
the pot of gold at the end of the rainbow.  
 
 
 
 
 
 
 
 
 
 
 
From Fairbanks, G. (1960). Voice and articulation drillbook, 2nd edn. New York: Harper & Row. pp124-139. 
 
 
